>>Atrial Natriuretic Peptide (3-28) (human) (trifluoroacetate salt)

Atrial Natriuretic Peptide (3-28) (human) (trifluoroacetate salt) (Synonyms: ANP (3-28) (human))

Catalog No.GC42872

Atrial natriuretic peptide (ANP) (3-28) is a synthetic and truncated form of ANP, which is an endogenous peptide generated by proteolysis of prepro-ANP that is secreted by cardiomyocytes in the heart.

Products are for research use only. Not for human use. We do not sell to patients.

Atrial Natriuretic Peptide (3-28) (human) (trifluoroacetate salt) Chemical Structure

Size 가격 재고 수량
500μg
US$199.00
재고 있음
1mg
US$338.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Atrial natriuretic peptide (ANP) (3-28) is a synthetic and truncated form of ANP, which is an endogenous peptide generated by proteolysis of prepro-ANP that is secreted by cardiomyocytes in the heart. ANP (3-28) potently inhibits renin release from cultured renal juxtaglomerular cells (Ki = 10 pM) in a cGMP-dependent manner. It also dose-dependently decreases mean arterial pressure (MAP) and arterial plasma renin activity and increases fractional sodium and calcium excretion, urine volume, and glomerular filtration rate in conscious dogs with a maximum effect attained when administered at a dose of 200 pM. ANP (3-28) (human) is a 26 amino acid peptide corresponding to the truncated human protein sequence.

리뷰

Review for Atrial Natriuretic Peptide (3-28) (human) (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 12 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Atrial Natriuretic Peptide (3-28) (human) (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.